Saratov JOURNAL of Medical and Scientific Research

Diagnostic implication of cytokines in musculoskeletal neoplasms

Year: 2019, volume 15 Issue: №4 Pages: 934-939
Heading: Рathophysiology Article type: Original article
Authors: Ponamarev I.R., Puchinyan D.M., Shchanitsyn I.N.
Organization: Saratov State Medical University
Summary:

Objective: to analyze diagnostic significance of neopterin, VEGF, sICAM, sVCAM, IL-6, TNF-a and MMP-9 in determining the nature of tumor process in musculoskeletal neoplasms. Material and Methods. 64 patients with benign (44) and malignant (20) musculoskeletal tumors aged 18to65y. o. were examined. Neopterin, VEGF, sICAM, sVCAM, IL-6, TNF-a and MMP-9 in serum were studied by enzyme immunoassay (p=0.07). Results. A statistically significant increase in the expression of regulatory molecules, neopterin (p<0.001), VEGF (p=0.02), slCAM-1 (p<0.001), IL-6 (p<0.001), TNF-a (p=0.02) in particular has been discovered and a pronounced tendency for the increase of MMP-9 level has been in evidence. Using ROC analysis, threshold values for each parameter have been determined. The most informative cytokines (neopterin, sICAM and IL-6) have been identified with multivariable regression method. Conclusion. The levels of neopterin, slCAM-1, IL-6 in the serum of patients with malignant musculoskeletal neoplasms above the threshold values predict an unfavorable course of the disease.

Bibliography:
1. International Agency for Research on Cancer WHO 'Cancer today' (Globocan 2018). URL: http://gco.iarc.fr/today/data/factsheets/cancers/39-AII-cancers-fact-sheet. pdf (March 21, 2019).
2. Michalak J, Bulska M, Strzbaia K, Szczesniak P. Neopterin as a marker of cellular immunological response. Postepy Hig Med Dosw (Online) 2017; 71 (1): 727-36.
3. Sucher R, Schroecksnadel K, Weiss G, et al. Neopterin, a prognostic marker in human malignancies. Cancer Lett 2010; 287(1): 13-22.
4. Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A, Kemona H. Prognostic significance of adhesion molecules (slCAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thrombosis Research 2012; 129 (4): 47-50.
5. O'Hanlon DM, Fitzsimons H, Lynch J, et al. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 2002; 38 (17): 2252-7.
6. Aydin Y, Kaplan I, Bilen Y, et al. Plasma levels of IL-6 and TNF-a in patients with esophageal cancer. Turk J Med Sci 2012; 42 (5): 762-7.
7. Sanguinete МММ, Oliveira PH, Martins-Filho A, et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest 2017; 46 (7): 677-88.
8. Wang L, Chang Y, Xu J, Zhang Q. Predictive significance of serum level of vascular endothelial growth factor in gastric cancer patients. Biomed Res Int 2016; 2016: 8103019.
9. Lin Q, Guo L, Lin G, et al. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiology 2015; 39: 539-44.
10. Jawicki S, GiaTewska EK, Sobolewska M, et al. Plasma levels and diagnostic utility of macrophage colony-stimulating factor, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 as new biomarkers of breast cancer. Ann Lab Med 2016; 36(3): 223-9.
11. Han YH, Gao B, Huang JH, et al. Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. Int J Clin Exp Pathol 2015; 8 (7): 8446-52.
12. Liao D, Huang H, Zhu Z, et al. Prognostic value of matrix metalloproteinase-9 in nasopharyngeal carcinoma: a meta-analysis. Minerva Med 2016; 107 (1): 54-61.
13. Wang RX, Chen S, Huang L, Shao ZM. Predictive and prognostic value of matrix metalloproteinase (MMP) — 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients. ВМС Cancer 2018; 18 (1): 909.
14. Babkina IV, Rousseau EYu, Soloviev YuN, et al. Content of soluble form of endothelial adhesion molecule of type 1 vessels (sVCAM-1) in blood serum of patients with bone tumors. Bone sarcomas, soft tissue and skin tumors 2012; 1: 52-4.
15. Khalilova VZ, Efendiyev AM, Akhmedova GA, Ibrahimov ЕЕ. lnterleukin-6 and TNF-a in the serum of patients with bone tumors. Medicines of Ukraine plus 2016; (3): 75-8.
16. Korshunov GV, Pavlenko NN, Puchinyan DM, Shakhmartova SG. Biomarkers content in blood serum of patients with osseous neoformations. Saratov Journal of Medical Scientific Research 2016; 12 (3): 358-61.
17. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Lyon: IARS Press, 2005; 435 p.

AttachmentSize
2019_04_934-939.pdf1013.44 KB

No votes yet